Avalyn Pharma (AVLN) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.67

Estimate

-$0.75

Surprise

+10.7%

Score today

5.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Avalyn Pharma (AVLN) reported a narrower loss than forecast — adjusted EPS of -$0.67 against the -$0.75 estimate (a 10.7% beat on a still-unprofitable quarter).

• Avalyn Pharma Reports Third Quarter 2026 Financial Results and Business Highlights — fiscal.ai, 2026-11-12
• Avalyn Pharma Q3 EPS $(0.67) Beats $(0.75) Estimate — benzinga, 2026-11-12

TrendMatrix currently rates AVLN Sell at 5.4/10; no pre/post engine snapshot brackets this report.

1 of the last 3 quarters beat the estimate; this quarter's +10.7% surprise compares with a -880.4% four-quarter average. Next scheduled report: 2027-03-18.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$30.28

Price target

$53.07

Stop

$28.16

Upside to target

+75.3%

Reward-to-risk

5.0:1

Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.35B

P/E (fwd)

-11.7

52-week range

$22.24–$40.17

Off 52-week high

24.6%

RSI (14)

65

Volume vs avg

1.16×

Score today

5.4/10